The study of the Mechanistic Target Of Rapamycin (mTOR) has evolved from a curious discovery in Easter Island soil to the cornerstone of modern longevity science. While early research focused on its immunosuppressive properties, current clinical interest centers on its role as the "master regulator" of cellular growth and aging. Understanding the precise structural mechanism…

In 2026, the discussion around longevity has moved from "What is the best pill?" to "How do we balance the pathways?" The debate over Rapamycin vs. Metformin for longevity has reached a turning point in 2026. While both molecules dominated early geroscience discussions, recent meta-analyses and clinical data now distinguish between "fringe benefits" and "fundamental…

For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…

For many people interested in living longer, the goal is simple: avoid the "Big Four" diseases of aging. At the top of that list is cancer. Modern science is moving away from just treating cancer after it appears and toward Rapamycin and cancer prevention as a way to stop the disease before it even starts.…

The pursuit of human longevity has transitioned from speculative "elixirs" to the rigorous science of geroprotection, with the mechanistic target of rapamycin (mTOR) pathway serving as a central hub. While Rapamycin is the most robust pharmacological intervention for extending lifespan in model organisms, its translation to healthy humans is complicated by its powerful metabolic footprint.…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…

For decades, the search for a true "longevity pill" was considered more science fiction than science. However, the discovery of the mTOR pathway and its inhibition by a soil-derived molecule called rapamycin has shifted that perspective. While animal studies have long shown that rapamycin can extend lifespan by up to 60%, the question of whether…

Can a drug originally used in organ transplant medicine hold the key to preventing Alzheimer’s disease? As we move into 2025, Rapamycin has transitioned from a niche "longevity molecule" to a primary subject of intense clinical investigation for dementia. Rapamycin is an FDA-approved mTOR inhibitor that researchers believe may slow the biological processes of aging…

For decades, people living with ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) have waited for treatments that address more than just symptoms. Now, new research led by Dr. Avik Roy at the Simmaron Research Institute suggests that an unexpected molecule—rapamycin—might help restore the underlying biology that drives fatigue in many patients. Why Rapamycin? A Closer…

Emerging evidence suggests that Rapamycin — an mTOR inhibitor long used in clinical settings — may suppress core aging mechanisms by moderating cellular hyperfunction, delaying age-related diseases, and extending lifespan across species. This positions Rapamycin and its analogs as serious candidates for “anti-aging” interventions in humans. Background: Why mTOR and Cellular Hyperfunction Matter in Aging…